Literature DB >> 9190864

Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part II.

R Testa1, L Guarneri, P Angelico, E Poggesi, C Taddei, G Sironi, D Colombo, A C Sulpizio, D P Naselsky, J P Hieble, A Leonardi.   

Abstract

The aim of the present work was to investigate whether or not the uroselectivity of Rec 15/2739 and several other alpha-1 adrenoceptor (alpha1-AR) antagonists observed in the anesthetized dog could be related to selectivity of these compounds for a particular alpha-1 AR subtype. The binding affinity of the tested compounds for canine prostate alpha-1 ARs and their in vitro functional affinity for the alpha-1 ARs of rabbit urethra and prostate correlated with their functional affinity for the alpha-1L AR subtype, but not with the binding affinity for recombinant animal and human alpha-1a, alpha-1b and alpha-1d AR subtypes. Similar results were obtained when the in vivo potency on urethral pressure was correlated with the affinity for the alpha-1 AR subtypes; also in this case alpha-1L AR gave the best correlation. No correlation was obtained by considering the other alpha-1 AR subtypes. The in vivo hypotensive effects observed in dog after i.v. administration of the considered compounds correlated only with the binding affinity for the animal and human alpha-1d subtype. In conclusion, the results shown in the present paper indicate that the potencies of different alpha-1 antagonists against the contractions induced by norepinephrine on tissues of the lower urinary tract of rabbits and dogs are better correlated with their affinity for the putative alpha-1L subtype than for the alpha-1a subtype. Only the compounds showing selectivity for the alpha-1L subtype versus the alpha-1d subtype proved highly selective in vivo for the lower urinary tract versus the vascular tissues.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9190864

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

1.  Quantitative structure-activity relationships of alpha1 adrenergic antagonists.

Authors:  Slavica Eric; Tomaz Solmajer; Jure Zupan; Marjana Novic; Marko Oblak; Danica Agbaba
Journal:  J Mol Model       Date:  2004-03-03       Impact factor: 1.810

2.  Agonist pharmacology at recombinant α1A - and α1L -adrenoceptors and in lower urinary tract α1 -adrenoceptors.

Authors:  Hatsumi Yoshiki; Junsuke Uwada; Hidenori Umada; Tadashi Kobayashi; Toshihiro Takahashi; Tomio Yamakawa; Akio Yamaguchi; Osamu Yokoyama; Ikunobu Muramatsu
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

3.  Alpha(1A)-adrenoceptors mediate contractions to phenylephrine in rabbit penile arteries.

Authors:  J S Morton; C J Daly; V M Jackson; J C McGrath
Journal:  Br J Pharmacol       Date:  2006-11-20       Impact factor: 8.739

4.  Identification of the alpha1L-adrenoceptor in rat cerebral cortex and possible relationship between alpha1L- and alpha1A-adrenoceptors.

Authors:  S Morishima; F Suzuki; H Yoshiki; A S Md Anisuzzaman; Z S Sathi; T Tanaka; I Muramatsu
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

5.  Alpha1A/B-knockout mice explain the native alpha1D-adrenoceptor's role in vasoconstriction and show that its location is independent of the other alpha1-subtypes.

Authors:  L Methven; P C Simpson; J C McGrath
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

6.  Pharmacologically distinct phenotypes of α1B -adrenoceptors: variation in binding and functional affinities for antagonists.

Authors:  Hatsumi Yoshiki; Junsuke Uwada; Abu Syed Md Anisuzzaman; Hidenori Umada; Ryoji Hayashi; Mie Kainoh; Takayoshi Masuoka; Matomo Nishio; Ikunobu Muramatsu
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 7.  Phenotype pharmacology of lower urinary tract α(1)-adrenoceptors.

Authors:  A Nishimune; H Yoshiki; J Uwada; A S M Anisuzzaman; H Umada; I Muramatsu
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

8.  In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha1A-adrenoceptor selective antagonists.

Authors:  T J Williams; D R Blue; D V Daniels; B Davis; T Elworthy; J R Gever; M S Kava; D Morgans; F Padilla; S Tassa; R L Vimont; C R Chapple; R Chess-Williams; R M Eglen; D E Clarke; A P Ford
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

9.  Native profiles of alpha(1A)-adrenoceptor phenotypes in rabbit prostate.

Authors:  T-H Su; S Morishima; F Suzuki; H Yoshiki; A S M Anisuzzaman; T Tanaka; J-T Cheng; I Muramatsu
Journal:  Br J Pharmacol       Date:  2008-08-11       Impact factor: 8.739

10.  The alpha 1B/D-adrenoceptor knockout mouse permits isolation of the vascular alpha 1A-adrenoceptor and elucidates its relationship to the other subtypes.

Authors:  L Methven; M McBride; G A Wallace; J C McGrath
Journal:  Br J Pharmacol       Date:  2009-06-30       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.